Blood Cancer Drug Shows Effectiveness in Trial

Monday, 04 Aug 2014 12:39 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
 
Amgen Inc said a late-stage study found that its blood cancer drug helped patients live significantly longer without the disease worsening, compared with standard treatment.
The world's largest biotechnology company's shares rose as much as 4.3 percent to $131.00 in premarket trading, after it released interim data for its injectable drug, Kyprolis.
The U.S. Food and Drug Administration, in 2012, granted the drug accelerated approval for use in multiple myeloma, the second most common form of blood cancer.
Accelerated approval is granted to drugs for serious diseases with little or no treatment options, based on data from initial trials. However, manufacturers still need to conduct larger trials to bolster initial findings.
The trial tested Kyprolis in combination with two other treatments, against those two treatments alone, in 792 patients with relapsed multiple myeloma who have received prior therapy.
Patients treated with Kyprolis lived for a median of 26.3 months without disease progression, compared with 17.6 months for those not given the drug, Amgen said.
The data may support the conversion of accelerated approval to full approval and help the company expand the current indication in the United States, Amgen said.
Amgen shares were up 3.14 percent at $129.50 in premarket trading on the Nasdaq on Monday.
Kyprolis, the centerpiece of Amgen's nearly $10 billion acquisition of Onyx Pharmaceuticals last year, had sales of $68 million in the first quarter.
 

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Food Pesticide Residue Nothing to Worry About: USDA

Saturday, 20 Dec 2014 10:26 AM

More than half of food tested by the U.S. government for pesticide residues last year showed detectable levels of pestic . . .

Beware of Holiday Allergy Triggers

Saturday, 20 Dec 2014 10:16 AM

The holidays can be anything but joyous for people with allergies when they contend with fresh trees, scented candles an . . .

Diagnose Your Kid's Ear Infection With Your iPhone

Friday, 19 Dec 2014 16:15 PM

Diagnosing your kid's ear infections might soon be as simple as taking a video on your smartphone. . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved